Lab guide · Melanocortin & kisspeptin analogues
What Is PT-141? Bremelanotide Melanocortin Peptide Research Overview
What is PT-141? It is bremelanotide, a cyclic heptapeptide melanocortin receptor agonist that shares the full ring of Melanotan II but ends in a free carboxylic acid instead of an amide. This guide covers its structure, how it differs from Melanotan II, its receptor profile and its regulatory position as the active ingredient of an FDA-approved medicine.
Key takeaways
- PT-141 (bremelanotide) is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10, molecular weight 1025.2 g/mol, CAS 189691-06-3.
- It differs from Melanotan II only at the C-terminus: a free carboxylic acid in PT-141 and an amide in Melanotan II.
- It is not receptor-selective; pharmacology across the melanocortin receptors is characterised, with MC4R central to hypothalamic research.
- Bremelanotide was granted FDA approval on 21 June 2019 as a prescription drug product; research-grade PT-141 is a different, unapproved reagent.
What is PT-141?
So, what is PT-141? PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide analogue of α-MSH. The FDA label describes it as a cyclic heptapeptide with a free acid at the carboxyl terminus and an acetylated amino group at the amino terminus, Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys-OH) (FDA label). PubChem classes it as a melanocortin receptor agonist (PubChem).
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Ring | Lactam between the Asp and Lys side chains |
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1025.2 g/mol (free base) |
| CAS number | 189691-06-3 |
| PubChem CID | 9941379 |
The formula, mass and CAS number match the PubChem record and the FDA review documents. The lactam ring is an amide between two side chains, not a disulfide. The free C-terminal acid is the only difference from Melanotan II, which has an amide and therefore a mass of 1024.2 g/mol, one dalton lower.
Discovery and research history
PT-141 grew out of α-MSH analogue work at the University of Arizona that produced Melanotan II. A 2000 review by Wessells and colleagues discusses melanocortin receptor agonists, penile erection and sexual motivation, and describes their experience with Melanotan II in human subjects. Bremelanotide was later developed commercially by Palatin Technologies, according to the supplier product page.
The FDA granted approval to a bremelanotide injection product, Vyleesi, on 21 June 2019 (PubChem, citing DrugBank). LiverTox states that it was approved for use in the United States in 2019 for premenopausal women with hypoactive sexual desire disorder.
Mechanism: melanocortin receptor agonism
Receptor profile
PT-141 is not receptor-selective. Published pharmacology shows agonist activity at MC1R, MC3R, MC4R and MC5R, which are Gs-coupled receptors whose activation raises cAMP. Research interest centres on the centrally expressed MC4R and MC3R, while MC1R activity is associated with pigmentary effects.
Interpreting the pathway
Because several receptors are activated, a single endpoint cannot be assigned to one receptor without selective antagonists or genetic models. The clinical mechanism of the approved product is not described here beyond what the regulatory documents state.
Main research areas
- Melanocortin receptor pharmacology: binding and functional assays across MC1R to MC5R, compared with α-MSH and Melanotan II.
- Central melanocortin pathways: hypothalamic MC4R and MC3R signalling in preclinical models.
- Pigmentation biology: MC1R signalling in melanocytes.
- Energy homeostasis: MC4R as a regulator of appetite and energy balance.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula, mass and CAS number are in FDA documents and PubChem. |
| Receptor pharmacology | Agonism at MC1R, MC3R, MC4R and MC5R without receptor selectivity. |
| Regulatory | FDA approval on 21 June 2019 for a specific prescription product; not described here as applying to research-grade material. |
| Unconfirmed | Receptor-specific attribution of effects, and any effect of research-grade material outside experimental settings. |
The approval concerns a defined pharmaceutical product with its own formulation, labelling and clinical programme. It does not make research-grade PT-141 a medicine.
Scientific limitations and open questions
- Non-selective receptor activation makes mechanistic attribution difficult.
- The FDA approval concerns one pharmaceutical product and indication, and should not be generalised to research-grade material.
- Bremelanotide is not authorised as a medicinal product in the EU, according to the supplier product page.
- Comparisons with Melanotan II depend on small structural differences that are not fully characterised in every receptor system.
Analytical and laboratory considerations
Mass spectrometry should show the cyclic peptide near 1025.2 Da. The free acid distinguishes it from Melanotan II (1024.2 Da), so the two are separable by mass; they are also separable by HPLC. Tryptophan and histidine are oxidation-sensitive, and a lactam ring is not affected by reducing agents. HPLC should also resolve the D-Phe diastereomer, which has the same mass.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the PT-141 product page.
Sources and further reading
- US FDA label for Vyleesi (bremelanotide), structure and formula. FDA label data
- FDA review documents, NDA 210557 (bremelanotide structure, CAS 189691-06-3, molecular weight 1025.182). FDA
- Bremelanotide, LiverTox, NCBI Bookshelf. NCBI
- Wessells H. et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation. PubMed · PubChem: Bremelanotide
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is PT-141?
What is the molecular weight and CAS number of PT-141?
How is PT-141 different from Melanotan II?
Is PT-141 selective for MC4R?
Is PT-141 an approved medicine?
What does the lactam ring in PT-141 do?
How do you tell PT-141 from Melanotan II analytically?
Keep reading
Related reading
PT-141
Current batches, formats and the COA for PT-141.
What is Melanotan II?
The amide analogue with the same cyclic backbone.
What is Kisspeptin-10?
A different hypothalamic peptide system studied alongside melanocortins.
Research-grade PT-141, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
